Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Department of Psychiatry, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Obesity (Silver Spring). 2018 Feb;26(2):299-309. doi: 10.1002/oby.22081. Epub 2017 Dec 29.
Improving the maintenance of lost weight remains a critical challenge, which can be addressed by long-term behavioral and/or pharmacological interventions.
This study investigated the efficacy of combined behavioral and pharmacological treatment in facilitating weight loss maintenance (WLM) in 137 adults (86.1% female; 68.6% black; BMI = 37.0 ± 5.6 kg/m ) who had lost ≥ 5% of initial weight during a 14-week low-calorie diet (LCD) program (mean = 9.3 ± 2.9%). Participants were randomly assigned to lorcaserin (10 mg twice a day) or placebo and were provided 16 group WLM counseling sessions over 52 weeks.
At 24 weeks post randomization, more lorcaserin-treated than placebo-treated participants maintained a ≥ 5% loss (73.9% vs. 57.4%; P = 0.033), and the lorcaserin-treated participants lost an additional 2.4 ± 0.8 kg versus a 0.6 ± 0.8 kg gain for placebo (P = 0.010). However, at week 52, groups did not differ on either co-primary outcome; 55.1% and 42.6%, respectively, maintained ≥ 5% loss (P = 0.110), with gains from randomization of 2.0 ± 0.8 kg and 2.5 ± 0.8 kg (P = 0.630), respectively. From the start of the LCD, groups maintained reductions of 7.8% and 6.6%, respectively (P = 0.318).
Combined behavioral and pharmacological treatment produced clinically meaningful long-term weight loss in this group of predominantly black participants. Lorcaserin initially improved upon weight loss achieved with WLM counseling, but this advantage was not maintained at 1 year.
提高减肥后的维持率仍然是一个关键挑战,可以通过长期的行为和/或药物干预来解决。
本研究调查了联合行为和药物治疗在促进 137 名成年人(86.1%为女性;68.6%为黑人;BMI=37.0±5.6kg/m )减肥后维持体重(WLM)方面的疗效,这些参与者在 14 周的低热量饮食(LCD)计划中已经减轻了初始体重的≥5%(平均=9.3±2.9%)。参与者被随机分配到lorcaserin(每天两次,每次 10mg)或安慰剂组,并在 52 周内接受 16 次团体 WLM 咨询。
在随机分组后 24 周时,lorcaserin 治疗组比安慰剂组有更多的参与者维持了≥5%的减重(73.9%比 57.4%;P=0.033),lorcaserin 治疗组额外减轻了 2.4±0.8kg,而安慰剂组则增加了 0.6±0.8kg(P=0.010)。然而,在第 52 周时,两组在两个主要终点上都没有差异;分别有 55.1%和 42.6%的参与者维持了≥5%的减重(P=0.110),从随机分组开始的体重增加分别为 2.0±0.8kg 和 2.5±0.8kg(P=0.630)。从 LCD 开始,两组分别维持了 7.8%和 6.6%的体重减轻(P=0.318)。
在以黑人为主的参与者中,联合行为和药物治疗产生了具有临床意义的长期减肥效果。lorcaserin 最初改善了 WLM 咨询所达到的减重效果,但这种优势在 1 年内没有维持。